Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol

Journal of Clinical Pharmacology

Volumn 37, Issue 11, 1997, Pages 1073-1081

  Troy, Steven M ^a   Turner, Mary Beth ^a   Unruh, Mary ^a   Parker, Vernon D ^a   Chiang, Soong T ^a  

^a WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DESVENLAFAXINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; PHARMACODYNAMICS; PHARMACOKINETICS; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL;

EID: 0030862185     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04290.x     Document Type: Article

References (26)

1. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen T, Sigg EG: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986:35:4493-4497.
2. Haskins JT, Moyer JA, Muth EA, Sigg EB: Inhibition of noradrenergic neuronal activity by the novel bicyclic compounds, VVy45,030 and Wy-45,881. Soc Neurosci 1984; 10:262.
3. Muth EA, Moyer JA, Haskins JT, Andrée TH, Husbands GEM: Biochemical, neurophysiological, and behavioral effects of Wy45,233, its enantiomers, and other identified metabolites of the antidepressant venlafaxine. Drug DevRes 1991;23:191-199.
4. Muth EA, Moyer JA, Andrée TH: A pharmacological profile of Wy-45,233, the major metabolite in humans of the novel bicyclic antidepressant candidate, Wy-45,030. Soc Neurosci 1986; 12:47
5. Moyer JA, Muth EA, Haskins JT, Lappe RW, Sigg EB: In vivo antidepressant profiles of the novel bicyclic compounds Wy45,030 and Wy-45,881. Soc Neurosci 1984;10:261.
6. Rudorfer MV, Potter WZ: Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the newer versus the older drugs. Drugs 1989;37:713-738.
7. Howell SR, Husbands GEM, Scatina JA, Sisenwine SF: Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993:23:349-359.
8. Fatal A, Trocherie S, Le Coz F, Troy S, Burke J, Danjou P, Allain H, Gandon JM: Absolute bioavailability and EEG effects of CT & ER venlafaxine formulation. Clin Pharmacol Ther 1997; 61:180.
9. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM: Venlafaxine oxidation in vitro is catalysed by CYP2D6. Dr J Clin Pharmacol 1996;41:149-156.
10. Wechsler D: Manual for the Wechsler Adult Intelligence Scale-Revised. New York: The Psychological Corporation, 1981.
11. Smith JM, Misiak H: Critical flicker frequency (CFF) and psychotropic drugs in normal volunteers-a review. Psychopharmacology 1976:47:175-182.
12. Seidel WF, Cohen SA, Wilson L, Dement WC: Effects of alprazolam and diazepam on the daytime sleepiness of non-anxious volunteers. Psychopharmacology 1985;87:194-197.
13. Ghoneim MM, Hinrichs JV, Mewaldt SP: Dose-response anal-ysis of the behavioral effects of diazepam: I. Learning and memory. Psychopharmacology 1984:82:291-295.
14. McNair D, Lorr M, Droppleman L: Profile of Mood States (manual). San Diego: Educational and Industrial Testing Service, 1971.
15. Hicks DR, Wolaniuk D, Russell A, Cavanaugh N, Kraml M: A high-performance liquid Chromatographie method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids. Ther Drug Monit 1994:16:100-107.
16. Evans \VE, Schentag JJ, Jusko WJ: Applied Pharmacokinetics. 2nd ed. Spokane, Washington: Applied Therapeutics 1986:639-680.
17. Schuirmann DJ: A comparison of the two one-sided tests procedure for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15:657-680.
18. SAS Institute, Inc. SAS/STAT User's Guide, Version 6, 4th ed. Gary, NC: SAS Institute, Inc., 1990.
19. Winjnand HP, Timmer CJ: Mini-computer programs for bioequivalence testing of pharmaceutical drug formulations in twoway cross-over studies. Comput Methods Programs Biomed 1983;17:73-88.
20. Dorian P, Sellers EM, Reed KL, Warsh J, Hamilton C, Kaplan HL, Fan T: Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction. Eur J Clin Pharmacol 1983:24:325-331.
21. Warrington SJ, Ankier SI, Turner P. An evaluation of possible interactions between ethanol and trazodone or amitriptyline. Br J Clin Pharmacol 1984:18:549-557.
22. Edwards OJ, Bellevue FH, Woster PM: Identification of 6'-7'dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996;24:1287-1290.
23. Ducharme MP, Warbasse LH, Edwards DJ: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995:57:485-491.
24. Sellers EM, Naranjo CA, Giles HG, Frecker RC, Beeching M: Intravenous diazepam and oral ethanol interaction. Clin Pharmacol Ther 1980; 28:638-645.
25. Naranjo CA, Sellers EM, Kaplan HL, Hamilton C, Khouw V: Acute kinetic and dynamic interactions of zimolidine with ethanol. Clin Pharmacol Ther 1984;36:654-660.
26. Lemberger L, Rowe H, Bergstrom RF, Farid KZ, Enas GG: Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanol. Clin Pharmacol Ther 1985; 37:658-664.